BioAtla Inc

BioAtla Inc is a biopharmaceutical firm currently in the clinical development phase focused on creating highly specific and selective antibodyderived treatments designed to combat solid tumor cancers The companys primary experimental therapeutic BA3011 is a conditionally active biologic antibodydrug conjugate CAB ADC being investigated for its potential against soft tissue and bone sarcoma nonsmall cell lung cancer NSCLC and ovarian cancer Additionally BioAtla is advancing BA3021 another CAB ADC for a variety of solid malignancies such as NSCLC melanoma and ovarian cancer A third candidate BA3071 is a conditionally active anticytotoxic Tlymphocyteassociated antigen 4 CTLA4 antibody aimed at a broad spectrum of cancers including renal cell carcinoma nonsmall cell and small cell lung cancers hepatocellular carcinoma melanoma bladder cancer gastric cancer and cervical cancer Established in 2007 BioAtla Inc operates out of San Diego California